Section Arrow
IMMX.NASDAQ
- Immix Biopharma
Quotes are at least 15-min delayed:2025/11/17 07:27 EST
Pre Market
Last
 4.18
-0.03 (-0.71%)
Bid
4.1
Ask
4.21
High 4.29 
Low 4.18 
Volume 831 
Regular Hours
Last
 4.21
+0.6 (+16.62%)
Day High 
4.29 
Prev. Close
3.61 
1-M High
4.05 
Volume 
1.18M 
Bid
4.1
Ask
4.21
Day Low
3.5584 
Open
3.57 
1-M Low
2.31 
Market Cap 
121.22M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 3.38 
20-SMA 3.39 
50-SMA 2.69 
52-W High 4.05 
52-W Low 1.34 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.77/-0.78
Enterprise Value
122.23M
Balance Sheet
Book Value Per Share
0.25
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ASBPAspire Biopharma Holdings Inc.0.1063+0.0011+1.05%-- 
Pre Market 0.1038 -0.0025 -2.35%
CYPHCypherpunk Technologies Inc.2.75+0.99+56.25%-- 
Pre Market 3.52 +0.77 +28.00%
IVVDInvivyd2.35+0.58+32.77%-- 
Pre Market 2.39 +0.04 +1.70%
APLTApplied Therapeutics0.2183-0.0517-19.15%-- 
Pre Market 0.2688 +0.0505 +23.13%
RXRXRecursion Pharmaceuticals4.14-0.19-4.39%-- 
Pre Market 4.18 +0.04 +0.97%
Quotes are at least 15-min delayed:2025/11/17 07:27 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.